Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 9143
Country/Region: Kenya
Year: 2014
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $2,167,403 Additional Pipeline Funding: N/A

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

The goal of the HJF KDOD HIV Program is to mitigate the impact of HIV on the Kenyan military. HJF KDOD will support the scale up of combination prevention interventions among 135,000 soldiers, their dependants, and civilian employees with the aim of reducing new infections and decreasing AIDS-related mortality. For COP 2014 and 2015, emphasis will include strategic reallocation of resources towards the most cost effective, high impact and scientifically proven interventions including increasing the coverage of PMTCT, ART, VMMC, uptake of HTC, use of condoms, and other evidence based interventions.

In COP 2014, cost-effectiveness will be emphasized, supporting KDOD policy reform to optimize use of available health workforce, including expansion of task shifting, integration and decentralization of services, and leveraging central supply commodities. Commodity management, LIMS and EMR will be strengthened, transitioning some activities to KDOD to strategically reduce dependency on PEPFAR dollars and promote ownership by the KDOD. Monitoring and evaluation of planned activities against outcomes will be done quarterly ensuring resources are refocused and performance does not suffer. Implementation of the new MER strategy will enable a greater characterization of support provided to the KDOD to inform programmatic decisions.

HJF and the KDOD integrate HIV plans into the annual military performance contracts and will strengthen the capacity of KDOD HIV structures (Unit HIV committees). COP 2014 will support the development of a sustainability plan to ensure the KDOD leads, manages, coordinates, and over time increasingly finance their HIV program while sustaining programmatic quality and coverage goals as envisioned in the PEPFAR blueprint and the Global Health Initiative.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $103,825
Care: Orphans and Vulnerable Children (HKID) $20,000
Care: TB/HIV (HVTB) $151,304
Care: Pediatric Care and Support (PDCS) $55,583
Strategic Information (HVSI) $285,294
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $20,514
Prevention: HIV Testing and Counseling (HVCT) $117,000
Sexual Prevention: Other Sexual Prevention (HVOP) $273,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $121,894
Treatment: Adult Treatment (HTXS) $923,454
Treatment: Pediatric Treatment (PDTX) $95,535
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
C2.1.D_DSD By Age/Sex: 15+ Female 2015 1,472
C2.1.D_DSD By Age/Sex: 15+ Male 2015 1,508
C2.1.D_DSD By Age/Sex: <15 Female 2015 106
C2.1.D_DSD By Age/Sex: <15 Male 2015 114
C2.1.D_DSD By Age: 15+ 2015 2,980
C2.1.D_DSD By Age: <15 2015 220
C2.1.D_DSD By Sex: Female 2015 1,578
C2.1.D_DSD By Sex: Male 2015 1,622
C2.1.D_DSD Number of HIV-positive individuals receiving a minimum of one clinical service 2015 3,200
C2.1.D_DSD Sum of Age disaggregates 2015 3,200
C2.1.D_DSD Sum of Age/Sex disaggregates 2015 3,200
C2.1.D_DSD Sum of Sex disaggregates 2015 3,200
C2.1.D_NGI By Age/Sex: 15+ Female 2015 1,472
C2.1.D_NGI By Age/Sex: 15+ Male 2015 1,508
C2.1.D_NGI By Age/Sex: <15 Female 2015 106
C2.1.D_NGI By Age/Sex: <15 Male 2015 114
C2.1.D_NGI By Age: 15+ 2015 2,980
C2.1.D_NGI By Age: <15 2015 220
C2.1.D_NGI By Sex: Female 2015 1,578
C2.1.D_NGI By Sex: Male 2015 1,622
C2.1.D_NGI Number of HIV-positive individuals receiving a minimum of one clinical service 2015 3,200
C2.1.D_NGI Sum of Age disaggregates 2015 3,200
C2.1.D_NGI Sum of Age/Sex disaggregates 2015 3,200
C2.1.D_NGI Sum of Sex disaggregates 2015 3,200
C2.4.D_DSD Number of HIV-positive individuals receiving a minimum of one clinical service 2015 3,200
C2.4.D_DSD Number of HIV-positive patients who were screened for TB in HIV care or treatment setting 2015 3,200
C2.5.D_DSD Number of HIV-positive individuals receiving a minimum of one clinical service 2015 3,200
C2.5.D_DSD Number of HIV-positive patients in HIV care who started TB treatment 2015 112
CARE_CURR_DSD Age/sex: 1-4 Female 2015 34
CARE_CURR_DSD Age/sex: 1-4 Male 2015 20
CARE_CURR_DSD Age/sex: 10-14 Female 2015 40
CARE_CURR_DSD Age/sex: 10-14 Male 2015 54
CARE_CURR_DSD Age/sex: 15-19 Female 2015 47
CARE_CURR_DSD Age/sex: 15-19 Male 2015 20
CARE_CURR_DSD Age/sex: 20-24 Female 2015 124
CARE_CURR_DSD Age/sex: 20-24 Male 2015 23
CARE_CURR_DSD Age/sex: 25-49 Female 2015 1,227
CARE_CURR_DSD Age/sex: 25-49 Male 2015 1,095
CARE_CURR_DSD Age/sex: 5-9 Female 2015 28
CARE_CURR_DSD Age/sex: 5-9 Male 2015 37
CARE_CURR_DSD Age/sex: 50+ Female 2015 74
CARE_CURR_DSD Age/sex: 50+ Male 2015 370
CARE_CURR_DSD Age/sex: <1 Female 2015 4
CARE_CURR_DSD Age/sex: <1 Male 2015 3
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 1,472
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 1,508
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 106
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 114
CARE_CURR_DSD Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 3,200
CARE_CURR_DSD Sum of Age/Sex disaggregates 2015 3,200
CARE_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2015 3,200
CARE_NEW_DSD Age/sex: 1-4 Female 2015 6
CARE_NEW_DSD Age/sex: 1-4 Male 2015 5
CARE_NEW_DSD Age/sex: 10-14 Female 2015 3
CARE_NEW_DSD Age/sex: 10-14 Male 2015 4
CARE_NEW_DSD Age/sex: 15-19 Female 2015 4
CARE_NEW_DSD Age/sex: 15-19 Male 2015 2
CARE_NEW_DSD Age/sex: 20-24 Female 2015 20
CARE_NEW_DSD Age/sex: 20-24 Male 2015 3
CARE_NEW_DSD Age/sex: 25-49 Female 2015 96
CARE_NEW_DSD Age/sex: 25-49 Male 2015 71
CARE_NEW_DSD Age/sex: 5-9 Female 2015 4
CARE_NEW_DSD Age/sex: 5-9 Male 2015 2
CARE_NEW_DSD Age/sex: 50+ Female 2015 6
CARE_NEW_DSD Age/sex: 50+ Male 2015 19
CARE_NEW_DSD Age/sex: <1 Female 2015 2
CARE_NEW_DSD Age/sex: <1 Male 2015 3
CARE_NEW_DSD Aggregated Age/sex: 15+ Female 2015 126
CARE_NEW_DSD Aggregated Age/sex: 15+ Male 2015 95
CARE_NEW_DSD Aggregated Age/sex: <15 Female 2015 15
CARE_NEW_DSD Aggregated Age/sex: <15 Male 2015 14
CARE_NEW_DSD Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 250
CARE_NEW_DSD Sum of Age/sex disaggregates 2015 250
CARE_NEW_DSD Sum of Aggregated Age/sex disaggregates 2015 250
CARE_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 10
CARE_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services 2015 10
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 10
CARE_SITE Sum of Denominator Site Support Type disaggregates 2015 10
CARE_SITE Sum of Numerator Site Support Type disaggregates 2015 10
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 10
FN_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition 2015 16
FN_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services 2015 17
FN_SITE Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition 2015 16
FN_SITE Sum of Denominator Support Type disaggregates 2015 17
FN_SITE Sum of Numerator Support Type disaggregates 2015 16
FN_SITE Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services 2015 17
FN_THER_DSD Age: 1-4 2015 35
FN_THER_DSD Age: 15-17 2015 71
FN_THER_DSD Age: 18+ 2015 2,208
FN_THER_DSD Age: 5-14 2015 120
FN_THER_DSD Age: <1 2015 2
FN_THER_DSD Aggregated Age: 18+ 2015 2,208
FN_THER_DSD Aggregated Age: <18 2015 228
FN_THER_DSD Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2015 2,436
FN_THER_DSD Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2015 3,200
FN_THER_DSD Sum of Age disaggregates 2015 2,436
FN_THER_DSD Sum of Aggregated Age disaggregates 2015 2,436
FPINT_SITE_DSD By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 17
FPINT_SITE_DSD By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points 2015 17
FPINT_SITE_DSD Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 17
FPINT_SITE_DSD Service delivery type: Clinical 2015 17
FPINT_SITE_DSD Sum of Denominator Site Support Type disaggregates 2015 17
FPINT_SITE_DSD Sum of Numerator Site Support Type disaggregates 2015 17
FPINT_SITE_DSD Sum of Service Delivery Type disaggregates 2015 17
FPINT_SITE_DSD Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment 2015 17
HTC_TST_DSD Age/sex: 1-4 Female 2015 1,010
HTC_TST_DSD Age/sex: 1-4 Male 2015 1,720
HTC_TST_DSD Age/sex: 10-14 Female 2015 722
HTC_TST_DSD Age/sex: 10-14 Male 2015 1,229
HTC_TST_DSD Age/sex: 15-19 Female 2015 1,443
HTC_TST_DSD Age/sex: 15-19 Male 2015 2,457
HTC_TST_DSD Age/sex: 20-24 Female 2015 3,608
HTC_TST_DSD Age/sex: 20-24 Male 2015 6,143
HTC_TST_DSD Age/sex: 25-49 Female 2015 5,772
HTC_TST_DSD Age/sex: 25-49 Male 2015 9,826
HTC_TST_DSD Age/sex: 5-9 Female 2015 433
HTC_TST_DSD Age/sex: 5-9 Male 2015 737
HTC_TST_DSD Age/sex: 50+ Female 2015 1,443
HTC_TST_DSD Age/sex: 50+ Male 2015 2,457
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 12,266
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 20,885
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 2,164
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 3,685
HTC_TST_DSD By Test Result: Negative 2015 38,300
HTC_TST_DSD By Test Result: Positive 2015 700
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 39,000
HTC_TST_DSD Sum of Age/Sex disaggregates 2015 39,000
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2015 33,151
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2015 5,849
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2015 39,000
HTC_TST_DSD Sum of Test Result disaggregates 2015 39,000
HTC_TST_NGI Age/sex: 1-4 Female 2015 1,010
HTC_TST_NGI Age/sex: 1-4 Male 2015 1,720
HTC_TST_NGI Age/sex: 10-14 Female 2015 722
HTC_TST_NGI Age/sex: 10-14 Male 2015 1,229
HTC_TST_NGI Age/sex: 15-19 Female 2015 1,443
HTC_TST_NGI Age/sex: 15-19 Male 2015 2,457
HTC_TST_NGI Age/sex: 20-24 Female 2015 3,608
HTC_TST_NGI Age/sex: 20-24 Male 2015 6,143
HTC_TST_NGI Age/sex: 25-49 Female 2015 5,772
HTC_TST_NGI Age/sex: 25-49 Male 2015 9,826
HTC_TST_NGI Age/sex: 5-9 Female 2015 433
HTC_TST_NGI Age/sex: 5-9 Male 2015 737
HTC_TST_NGI Age/sex: 50+ Female 2015 1,443
HTC_TST_NGI Age/sex: 50+ Male 2015 2,457
HTC_TST_NGI Aggregated Age/sex: 15+ Female 2015 12,266
HTC_TST_NGI Aggregated Age/sex: 15+ Male 2015 20,885
HTC_TST_NGI Aggregated Age/sex: <15 Female 2015 2,164
HTC_TST_NGI Aggregated Age/sex: <15 Male 2015 3,685
HTC_TST_NGI By Test Result: Negative 2015 38,300
HTC_TST_NGI By Test Result: Positive 2015 700
HTC_TST_NGI Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 39,000
HTC_TST_NGI Sum of Age/Sex disaggregates 2015 39,000
HTC_TST_NGI Sum of Aggregated Age/Sex 15+ 2015 33,151
HTC_TST_NGI Sum of Aggregated Age/Sex <15 2015 5,849
HTC_TST_NGI Sum of Aggregated Age/Sex disaggregates 2015 39,000
HTC_TST_NGI Sum of Test Result disaggregates 2015 39,000
LAB_ACC_DSD By site support type: Direct Service Delivery (DSD) 2015 2
LAB_ACC_DSD Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 2
LAB_ACC_DSD Sum of Support Type disaggregates 2015 2
LAB_CAP_DSD By clinical laboratories 2015 15
LAB_CAP_DSD By Point-of-care testing sites 2015 5
LAB_CAP_DSD By site support type: Direct Service Delivery (DSD) 2015 15
LAB_CAP_DSD Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 15
LAB_CAP_DSD Sum of Site Support Type disaggregates 2015 15
LAB_PT_DSD CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 4
LAB_PT_DSD CD4: Number of laboratories that participate in this PT program 2015 4
LAB_PT_DSD CD4: Number of laboratories that perform this testing 2015 4
LAB_PT_DSD Early infant diagnostics: Number of laboratories that perform this testing 2015 8
LAB_PT_DSD HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 8
LAB_PT_DSD HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2015 8
LAB_PT_DSD HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2015 8
LAB_PT_DSD HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 1
LAB_PT_DSD HIV viral load: Number of laboratories that participate in this PT program 2015 1
LAB_PT_DSD HIV viral load: Number of laboratories that perform this testing 2015 1
LAB_PT_DSD Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program 2015 100
LAB_PT_DSD TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 8
LAB_PT_DSD TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program 2015 8
LAB_PT_DSD TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing 2015 8
OVC_ACC_DSD Age: 1-4 2015 54
OVC_ACC_DSD Age: 10-14 2015 94
OVC_ACC_DSD Age: 5-9 2015 65
OVC_ACC_DSD Age: <1 2015 7
OVC_ACC_DSD Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2015 220
OVC_ACC_DSD Sex: Female 2015 106
OVC_ACC_DSD Sex: Male 2015 114
OVC_ACC_DSD Sum of Age disaggregates 2015 220
OVC_ACC_DSD Sum of Sex disaggregates 2015 220
OVC_SERV_DSD Age: 1-4 2015 42
OVC_SERV_DSD Age: 10-14 2015 52
OVC_SERV_DSD Age: 15-17 2015 52
OVC_SERV_DSD Age: 18+ 2015 42
OVC_SERV_DSD Age: 5-9 2015 52
OVC_SERV_DSD Age: <1 2015 10
OVC_SERV_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2015 250
OVC_SERV_DSD Sex: Female 2015 93
OVC_SERV_DSD Sex: Male 2015 157
OVC_SERV_DSD Sum of Age disaggregates 2015 250
OVC_SERV_DSD Sum of Sex disaggregates 2015 250
PMTCT_ARV_DSD Life-long ART (including Option B+) 2015 107
PMTCT_ARV_DSD Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 36
PMTCT_ARV_DSD Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 143
PMTCT_ARV_DSD Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 143
PMTCT_ARV_DSD Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 57
PMTCT_ARV_DSD Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 50
PMTCT_ARV_DSD Sum of New and Current disaggregates 2015 107
PMTCT_ARV_DSD Sum of Regimen Type disaggregates 2015 143
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 107
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 36
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 143
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 143
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 57
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 50
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 107
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 143
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2015 136
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2015 7
PMTCT_EID_DSD By infants with a positive virologic test result within 12 months of birth 2015 2
PMTCT_EID_DSD Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 143
PMTCT_EID_DSD Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 143
PMTCT_EID_DSD Sum of Infant Age disaggregates 2015 143
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 17
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 17
PMTCT_SITE Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 17
PMTCT_SITE Sum of Denominator Support Type disaggregates 2015 17
PMTCT_SITE Sum of Numerator Support Type disaggregates 2015 17
PMTCT_SITE Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 17
PMTCT_STAT_DSD By: Known positives at entry 2015 57
PMTCT_STAT_DSD By: Number of new positives identified 2015 86
PMTCT_STAT_DSD Number of new ANC and L&D clients 2015 3,050
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 3,050
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2015 143
PMTCT_STAT_NGI By: Known positives at entry 2015 57
PMTCT_STAT_NGI By: Number of new positives identified 2015 86
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 3,050
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 3,050
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 143
PP_PREV_DSD Age/sex: 10-14 Female 2015 1,083
PP_PREV_DSD Age/sex: 10-14 Male 2015 1,083
PP_PREV_DSD Age/sex: 15-19 Female 2015 2,167
PP_PREV_DSD Age/sex: 15-19 Male 2015 2,167
PP_PREV_DSD Age/sex: 20-24 Female 2015 5,417
PP_PREV_DSD Age/sex: 20-24 Male 2015 5,417
PP_PREV_DSD Age/sex: 25-49 Female 2015 8,665
PP_PREV_DSD Age/sex: 25-49 Male 2015 8,667
PP_PREV_DSD Age/sex: 50+ Female 2015 2,167
PP_PREV_DSD Age/sex: 50+ Male 2015 2,167
PP_PREV_DSD Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 39,000
PP_PREV_DSD Sum of Age/Sex disaggregates 2015 39,000
PP_PREV_DSD Total number of people in the target population 2015 135,000
QI_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months 2015 10
QI_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC 2015 10
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 10
QI_SITE Sum of Denominator Site Support Type disaggregates 2015 10
QI_SITE Sum of Numerator Site Support Type disaggregates 2015 10
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 10
SITE_SUPP By program area/support type: Care and Support Direct Service Delivery (DSD) 2015 10
SITE_SUPP By program area/support type: Food and Nutrition Direct Service Delivery (DSD) 2015 17
SITE_SUPP By program area/support type: General Population Prevention Direct Service Delivery (DSD) 2015 31
SITE_SUPP By program area/support type: HTC Direct Service Delivery (DSD) 2015 31
SITE_SUPP By program area/support type: Lab Direct Service Delivery (DSD) 2015 15
SITE_SUPP By program area/support type: OVC Direct Service Delivery (DSD) 2015 31
SITE_SUPP By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD) 2015 17
SITE_SUPP By program area/support type: PMTCT Direct Service Delivery (DSD) 2015 17
SITE_SUPP By program area/support type: TB/HIV Direct Service Delivery (DSD) 2015 10
SITE_SUPP By program area/support type: Treatment Direct Service Delivery (DSD) 2015 10
SITE_SUPP By program area/support type: VMMC Direct Service Delivery (DSD) 2015 10
SITE_SUPP Number of unique sites supported by PEPFAR 2015 31
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units 2015 10
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 10
TB_ARTSITE Sum of Denominator Site Support Type disaggregates 2015 10
TB_ARTSITE Sum of Numerator Site Support Type disaggregates 2015 10
TB_ARTSITE The number of PEPFAR-supported TB basic management units 2015 10
TB_ARTSITE The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 10
TB_ART_DSD Age: 15+ 2015 110
TB_ART_DSD Age: 5-14 2015 2
TB_ART_DSD Aggregated Age: 15+ 2015 110
TB_ART_DSD Aggregated Age: <15 2015 2
TB_ART_DSD Female 2015 41
TB_ART_DSD Known HIV-positive 2015 45
TB_ART_DSD Male 2015 71
TB_ART_DSD Newly tested 2015 67
TB_ART_DSD Sum of Aggregated Age disaggregates 2015 112
TB_ART_DSD Sum of Sex disaggregates 2015 112
TB_ART_DSD Sum of Test Status disaggregates 2015 112
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2015 112
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 112
TB_SCREEN_DSD Age: 1-4 2015 54
TB_SCREEN_DSD Age: 10-14 2015 94
TB_SCREEN_DSD Age: 15-19 2015 67
TB_SCREEN_DSD Age: 20-24 2015 148
TB_SCREEN_DSD Age: 25-49 2015 2,322
TB_SCREEN_DSD Age: 5-9 2015 64
TB_SCREEN_DSD Age: 50+ 2015 444
TB_SCREEN_DSD Age: <1 2015 7
TB_SCREEN_DSD Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 2,981
TB_SCREEN_DSD Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2015 219
TB_SCREEN_DSD Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 3,200
TB_SCREEN_DSD Sex: Female 2015 1,622
TB_SCREEN_DSD Sex: Male 2015 1,578
TB_SCREEN_DSD Sum of Age disaggregates 2015 286
TB_SCREEN_DSD Sum of Aggregated Age disaggregates 2015 3,200
TB_SCREEN_DSD Sum of Sex disaggregates 2015 3,200
TB_SCREEN_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 3,200
TX_CURR_DSD Age/Sex: 1-4 Female 2015 28
TX_CURR_DSD Age/Sex: 1-4 Male 2015 23
TX_CURR_DSD Age/Sex: 15+ Female 2015 1,165
TX_CURR_DSD Age/Sex: 15+ Male 2015 1,374
TX_CURR_DSD Age/Sex: 5-14 Female 2015 54
TX_CURR_DSD Age/Sex: 5-14 Male 2015 88
TX_CURR_DSD Age/Sex: <1 Female 2015 3
TX_CURR_DSD Age/Sex: <1 Male 2015 4
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2015 1,165
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2015 1,374
TX_CURR_DSD Aggregated Age/Sex: <1 Female 2015 3
TX_CURR_DSD Aggregated Age/Sex: <1 Male 2015 4
TX_CURR_DSD Aggregated Age/Sex: <15 Female 2015 85
TX_CURR_DSD Aggregated Age/Sex: <15 Male 2015 115
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2015 2,739
TX_CURR_DSD Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 8
TX_CURR_DSD Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 42
TX_CURR_DSD Sum of age/sex disaggregates 2015 200
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2015 2,539
TX_CURR_DSD Sum of Aggregated Age/Sex <15 2015 200
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2015 2,739
TX_CURR_NGI Age/Sex: 1-4 Female 2015 28
TX_CURR_NGI Age/Sex: 1-4 Male 2015 23
TX_CURR_NGI Age/Sex: 15+ Female 2015 1,116
TX_CURR_NGI Age/Sex: 15+ Male 2015 1,325
TX_CURR_NGI Age/Sex: 5-14 Female 2015 54
TX_CURR_NGI Age/Sex: 5-14 Male 2015 88
TX_CURR_NGI Age/Sex: <1 Female 2015 3
TX_CURR_NGI Age/Sex: <1 Male 2015 4
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 1,116
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 1,325
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 3
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 4
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 85
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 115
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 2,641
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 2,641
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 2,441
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 200
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 2,641
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2015 174
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2015 147
TX_NEW_DSD Aggregated Grouping by Age/Sex: <1 Female 2015 3
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Female 2015 9
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Male 2015 11
TX_NEW_DSD Aggregated Grouping by Age: <1 Male 2015 4
TX_NEW_DSD By Age/Sex: 1-4 Female 2015 2
TX_NEW_DSD By Age/Sex: 1-4 Male 2015 2
TX_NEW_DSD By Age/Sex: 10-14 Female 2015 2
TX_NEW_DSD By Age/Sex: 10-14 Male 2015 3
TX_NEW_DSD By Age/Sex: 15-19 Female 2015 3
TX_NEW_DSD By Age/Sex: 15-19 Male 2015 3
TX_NEW_DSD By Age/Sex: 20-24 Female 2015 20
TX_NEW_DSD By Age/Sex: 20-24 Male 2015 4
TX_NEW_DSD By Age/Sex: 25-49 Female 2015 137
TX_NEW_DSD By Age/Sex: 25-49 Male 2015 109
TX_NEW_DSD By Age/Sex: 5-9 Female 2015 2
TX_NEW_DSD By Age/Sex: 5-9 Male 2015 2
TX_NEW_DSD By Age/Sex: 50+ Female 2015 14
TX_NEW_DSD By Age/Sex: 50+ Male 2015 31
TX_NEW_DSD By Age/Sex: <1 Female 2015 3
TX_NEW_DSD By Age/Sex: <1 Male 2015 4
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 341
TX_NEW_DSD Pregnancy status 2015 34
TX_NEW_DSD Sum of Age/Sex disaggregates 2015 341
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2015 341
TX_RET_DSD Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 11
TX_RET_DSD Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 9
TX_RET_DSD Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 321
TX_RET_DSD Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 257
TX_RET_DSD Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 9
TX_RET_DSD Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 7
TX_RET_DSD Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 321
TX_RET_DSD Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 20
TX_RET_DSD Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 257
TX_RET_DSD Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 16
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 273
TX_RET_DSD Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 34
TX_RET_DSD Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 27
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 341
TX_SITE By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 10
TX_SITE By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites 2015 10
TX_SITE Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 10
TX_SITE Sum of Denominator Site Support Type disaggregates 2015 10
TX_SITE Sum of Numerator Site Support Type disaggregates 2015 10
TX_SITE Total number of PEPFAR-supported ART sites 2015 10
VMMC_CIRC_DSD By Age: 10-14 2015 42
VMMC_CIRC_DSD By Age: 15-19 2015 14
VMMC_CIRC_DSD By Age: 20-24 2015 11
VMMC_CIRC_DSD By Age: 25-49 2015 5
VMMC_CIRC_DSD By Age: 50+ 2015 3
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2015 74
VMMC_CIRC_DSD By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 74
VMMC_CIRC_DSD By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 73
VMMC_CIRC_DSD By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 1
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 75
VMMC_CIRC_DSD Sum of age disaggregates 2015 75
VMMC_CIRC_NGI By Age: 10-14 2015 42
VMMC_CIRC_NGI By Age: 15-19 2015 14
VMMC_CIRC_NGI By Age: 20-24 2015 11
VMMC_CIRC_NGI By Age: 25-49 2015 5
VMMC_CIRC_NGI By Age: 50+ 2015 3
VMMC_CIRC_NGI By circumcision technique: Surgical VMMC 2015 74
VMMC_CIRC_NGI By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 74
VMMC_CIRC_NGI By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 73
VMMC_CIRC_NGI By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 1
VMMC_CIRC_NGI Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 75
VMMC_CIRC_NGI Sum of Age disaggregates 2015 75
Cross Cutting Budget Categories and Known Amounts Total: $400,000
Human Resources for Health $300,000
Food and Nutrition: Policy, Tools, and Service Delivery $50,000
Food and Nutrition: Commodities $50,000
Key Issues Identified in Mechanism
Child Survival Activities
Military Populations
Mobile Populations
Safe Motherhood
Tuberculosis
Family Planning